Advertisement

Topics

[Comment] Quality of life: an important element of treatment value

23:08 EST 9 Nov 2017 | The Lancet

In the era of platinum-based chemotherapy, attempts to improve the quality of life (QOL) of patients with advanced non-small-cell lung cancer (NSCLC) using a less toxic treatment than the existing standard therapy were often disappointing. In a randomised trial1 comparing cisplatin-based treatment to a so-called platinum-free combination chemotherapy, the goal of improving QOL was not met. The lesson learned was that in patients with a disease often associated with serious symptoms, reduction of treatment-related toxicity is not enough to improve global QOL, and more effective control of disease is needed to achieve a positive QOL balance.

Original Article: [Comment] Quality of life: an important element of treatment value

NEXT ARTICLE

More From BioPortfolio on "[Comment] Quality of life: an important element of treatment value"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Lung Cancer
Lung cancer is the uncontrolled cell growth in tissues of the lung. Originating in the lungs, this growth may invade adjacent tissues and infiltrate beyond the lungs. Lung cancer, the most common cause of cancer-related death in men and women, is respons...

Gilotrif (afatinib)
GILOTRIF (afatinib) is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L8...